HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Boosting Treg activity by TNFR2 and GITR agonists: new therapeutic approaches for autoimmune diseases].

AuthorsMorgane Hilaire, Nicolas Aubert
JournalMedecine sciences : M/S (Med Sci (Paris)) 2019 Aug-Sep Vol. 35 Issue 8-9 Pg. 702-705 ISSN: 1958-5381 [Electronic] France
Vernacular TitleLa stimulation des lymphocytes Treg via le TNFR2 et GITR comme nouvelle approche thérapeutique dans les maladies auto-immunes.
PMID31532385 (Publication Type: News)
Chemical References
  • Antibodies, Monoclonal
  • Glucocorticoid-Induced TNFR-Related Protein
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor, Type II
  • TNFRSF18 protein, human
  • Tnfrsf1b protein, mouse
  • Tumor Necrosis Factor-alpha
  • TOR Serine-Threonine Kinases
  • Sirolimus
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology, therapeutic use)
  • Autoimmune Diseases (drug therapy, immunology)
  • Cell Division (drug effects)
  • Drug Evaluation, Preclinical
  • Encephalomyelitis, Autoimmune, Experimental (drug therapy)
  • Glucocorticoid-Induced TNFR-Related Protein (agonists)
  • Humans
  • Immune Tolerance
  • Immunosuppressive Agents (pharmacology, therapeutic use)
  • Leukocytes, Mononuclear (immunology)
  • Mice
  • Molecular Targeted Therapy
  • Receptors, Tumor Necrosis Factor, Type II (agonists, deficiency)
  • Sepsis (immunology, therapy)
  • Sirolimus (pharmacology, therapeutic use)
  • T-Lymphocytes, Regulatory (drug effects, immunology)
  • TOR Serine-Threonine Kinases (immunology)
  • Tumor Necrosis Factor-alpha (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: